PART I Item 1. B usiness Our Business Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy. Our lead clinical program is botensilimab (BOT or AGEN1181), alone and in combinat...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-108632 | EDGAR | 100K words |
| 2025-03-17 | 2024-12-31 | 0000950170-25-040289 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031620 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008517 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007867 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013619 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011221 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001564590-19-008311 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001564590-18-006093 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004618 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-274554 | EDGAR | 27K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106633 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069396 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125608 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093937 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053951 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062051 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039768 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019649 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022915 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028592 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019080 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001193125-26-125170 | EDGAR | 1K words |
| 2026-03-16 | 0001193125-26-107288 | EDGAR | — |
| 2026-01-16 | 0001193125-26-014678 | EDGAR | — |
| 2026-01-14 | 0001193125-26-012922 | EDGAR | — |
| 2026-01-08 | 0001193125-26-007706 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273266 | EDGAR | — |
| 2025-10-09 | 0001193125-25-235819 | EDGAR | — |
| 2025-09-23 | 0001193125-25-213574 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106235 | EDGAR | — |
| 2025-06-20 | 0000950170-25-088502 | EDGAR | — |
261 total filings indexed. 229 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001098972 |
| Ticker | AGEN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.agenusbio.com |
| Listed | 2000-02-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report